An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines

The tyrosine kinase inhibitor (TKI) cabozantinib might impede the growth of the sunitinib-resistant cell lines by targeting MET and AXL overexpression in metastatic renal cell carcinoma (mRCC). We studied the role of MET and AXL in the response to cabozantinib, particularly following long-term admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaccagnino, Angela, Vynnytska-Myronovska, Bozhena, Stöckle, Michael, Junker, Kerstin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058472/
https://www.ncbi.nlm.nih.gov/pubmed/36982721
http://dx.doi.org/10.3390/ijms24065648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058472/
https://www.ncbi.nlm.nih.gov/pubmed/36982721
http://dx.doi.org/10.3390/ijms24065648

Ejemplares similares